MX2023005491A - Métodos de preparación de células t rejuvenecidas, composiciones que las comprenden y métodos de uso de las mismas. - Google Patents
Métodos de preparación de células t rejuvenecidas, composiciones que las comprenden y métodos de uso de las mismas.Info
- Publication number
- MX2023005491A MX2023005491A MX2023005491A MX2023005491A MX2023005491A MX 2023005491 A MX2023005491 A MX 2023005491A MX 2023005491 A MX2023005491 A MX 2023005491A MX 2023005491 A MX2023005491 A MX 2023005491A MX 2023005491 A MX2023005491 A MX 2023005491A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- cells
- compositions
- rejuvenated
- making
- Prior art date
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 230000003716 rejuvenation Effects 0.000 title abstract 2
- 210000004027 cell Anatomy 0.000 abstract 3
- 230000008672 reprogramming Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/464488—NY-ESO
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/602—Sox-2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/603—Oct-3/4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/604—Klf-4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/606—Transcription factors c-Myc
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18811—Sendai virus
- C12N2760/18821—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18811—Sendai virus
- C12N2760/18841—Use of virus, viral particle or viral elements as a vector
- C12N2760/18842—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18811—Sendai virus
- C12N2760/18841—Use of virus, viral particle or viral elements as a vector
- C12N2760/18843—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente descripción se refiere en general a métodos de producción de células T rejuvenecidas, que comprenden poner en contacto células T con al menos un factor de reprogramación y reactivar las células contactadas y composiciones y métodos de uso de las mismas. La presente descripción también describe poblaciones de células preparadas de acuerdo con los métodos descritos en la presente. La descripción también proporciona métodos de tratamiento de pacientes usando poblaciones de células preparadas mediante los métodos descritos en la presente.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063117787P | 2020-11-24 | 2020-11-24 | |
US202163153881P | 2021-02-25 | 2021-02-25 | |
US202163165093P | 2021-03-23 | 2021-03-23 | |
PCT/US2021/060650 WO2022115492A1 (en) | 2020-11-24 | 2021-11-23 | Methods for making, compositions comprising, and methods of using rejuvenated t cells |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023005491A true MX2023005491A (es) | 2023-08-09 |
Family
ID=81657994
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023005491A MX2023005491A (es) | 2020-11-24 | 2021-11-23 | Métodos de preparación de células t rejuvenecidas, composiciones que las comprenden y métodos de uso de las mismas. |
Country Status (10)
Country | Link |
---|---|
US (1) | US20220162551A1 (es) |
EP (1) | EP4251742A1 (es) |
JP (1) | JP2023553815A (es) |
KR (1) | KR20230113767A (es) |
AU (1) | AU2021386370A1 (es) |
CA (1) | CA3172507A1 (es) |
IL (1) | IL302744A (es) |
MX (1) | MX2023005491A (es) |
TW (1) | TW202235094A (es) |
WO (1) | WO2022115492A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023201097A1 (en) * | 2022-04-15 | 2023-10-19 | Turn Biotechnologies, Inc. | Methods and compositions for immune cell rejuvenation and therapies using rejuvenated immune cells |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9206394B2 (en) * | 2010-02-03 | 2015-12-08 | The University Of Tokyo | Method for reconstructing immune function using pluripotent stem cells |
JP6584776B2 (ja) * | 2011-04-08 | 2019-10-02 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 細胞を幼若化するための方法 |
US20140162366A1 (en) * | 2012-08-31 | 2014-06-12 | Salk Institute For Biological Studies | Generation of vascular progenitor cells |
WO2015039100A1 (en) * | 2013-09-16 | 2015-03-19 | The Trustees Of The University Of Pennsylvania | Cd137 enrichment for efficient tumor infiltrating lymphocyte selection |
JP6928604B2 (ja) * | 2015-11-04 | 2021-09-01 | フェイト セラピューティクス,インコーポレイテッド | 万能性細胞のゲノム改変 |
WO2018209324A2 (en) * | 2017-05-11 | 2018-11-15 | The Broad Institute, Inc. | Methods and compositions of use of cd8+ tumor infiltrating lymphocyte subtypes and gene signatures thereof |
EP3752602A4 (en) * | 2018-02-14 | 2021-11-24 | Sunnybrook Research Institute | METHOD OF GENERATING CELLS OF THE T CELL LINE |
MX2020009491A (es) * | 2018-03-13 | 2020-10-28 | Univ Leland Stanford Junior | Reprogramacion celular transitoria para revertir el envejecimiento celular. |
-
2021
- 2021-11-23 EP EP21899058.8A patent/EP4251742A1/en active Pending
- 2021-11-23 CA CA3172507A patent/CA3172507A1/en active Pending
- 2021-11-23 AU AU2021386370A patent/AU2021386370A1/en active Pending
- 2021-11-23 IL IL302744A patent/IL302744A/en unknown
- 2021-11-23 MX MX2023005491A patent/MX2023005491A/es unknown
- 2021-11-23 US US17/534,341 patent/US20220162551A1/en active Pending
- 2021-11-23 WO PCT/US2021/060650 patent/WO2022115492A1/en active Application Filing
- 2021-11-23 JP JP2023531007A patent/JP2023553815A/ja active Pending
- 2021-11-23 KR KR1020237021098A patent/KR20230113767A/ko unknown
- 2021-11-24 TW TW110143832A patent/TW202235094A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
TW202235094A (zh) | 2022-09-16 |
IL302744A (en) | 2023-07-01 |
EP4251742A1 (en) | 2023-10-04 |
US20220162551A1 (en) | 2022-05-26 |
JP2023553815A (ja) | 2023-12-26 |
AU2021386370A1 (en) | 2023-06-22 |
KR20230113767A (ko) | 2023-08-01 |
WO2022115492A9 (en) | 2022-08-25 |
CA3172507A1 (en) | 2022-06-02 |
WO2022115492A1 (en) | 2022-06-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Dos Santos et al. | Ex vivo expansion of human mesenchymal stem cells: a more effective cell proliferation kinetics and metabolism under hypoxia | |
BR0311362A (pt) | métodos, composições e fatores de crescimento e de diferenciação para produzir células produtoras de insulina | |
MX2009004238A (es) | Metodos y composiciones para tratamiento de defectos oseos con poblaciones de celulas de placenta. | |
JP2015507921A5 (es) | ||
BR112019024637A2 (pt) | Método para produzir células progenitoras renais, célula progenitora renal, organoide renal, composição farmacêutica, e, agente terapêutico para uma doença renal. | |
MX339068B (es) | Metodos y composiciones para el tratamiento de defectos oseos con poblaciones de celulas placentarias. | |
MX339632B (es) | Metodo para producir adamts13 recombinante en cultivo celular. | |
BRPI0516969A (pt) | método de preparar uma composição terapêutica, composição terapêutica, e, método de tratar um paciente humano sofrendo de hematopoiese deficiente | |
MX2009002388A (es) | Uso de celulas humanas originarias de leucemia mieloide para la expresion de anticuerpos. | |
BRPI0509488A (pt) | suspensões de esperma para seleção de populações enriquecidas carregando cromossomo x ou y | |
MX2023005491A (es) | Métodos de preparación de células t rejuvenecidas, composiciones que las comprenden y métodos de uso de las mismas. | |
PH12021551241A1 (en) | Expansion of natural killer cells and ilc3 cells with novel aromatic compounds | |
MX2021013608A (es) | Composiciones y métodos de fabricacion de celulas t. | |
WO2022086846A3 (en) | Dna-containing polynucleotides and guides for crispr type v systems, and methods of making and using the same | |
BR112013012697A2 (pt) | "método para diminuir expressão, produção ou secreção de um fator angiogênico ou fator hipertrófico ou ambos por células-tronco mesenquimais, métodos para diminuir um efeito inibidor, um efeito deletério, e um efeito de apoptose de células-tronco mesenquimais, método para aumentar um efeito estimulador de células-tronco mesenquimais, composição, e, método para preparar cartilagem em um indivíduo diagnosticado com cartilagem doente ou danificada." | |
BR112022009836A2 (pt) | Método para fornecer células imunes com função aumentada | |
MX2021011608A (es) | Metodos ex vivo para producir celulas t terapeuticas y composiciones y metodos afines. | |
WO2011105821A3 (ko) | 무혈청 줄기 세포 배양 조성물, 이를 함유한 조직 재생용 조성물 및 이를 이용한 조직 재생 방법 | |
BR112012016128A2 (pt) | agente terapêutico (y-39983) para disfunção endotelial da córnea | |
MX2023009452A (es) | Aril sulfonamidas como agonistas de receptores de orexina. | |
WO2023150493A3 (en) | Cell therapy for diabetes | |
BR112016009619A2 (pt) | métodos para sacarificar um material celulósico e para produzir um produto de fermentação a partir de material celulósico | |
AR120475A1 (es) | Producción de células precursoras hematopoyéticas | |
MX2021005721A (es) | Proceso de fabricacion de celulas t mejorado. | |
MX2021006808A (es) | Novedosa psicosa-6-fosfato fosfatasa, composicion para la produccion de psicosa que comprende la misma y procedimiento para la produccion de psicosa mediante el uso de la misma. |